Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
Last trade$13.32
Day change+$0.03 (+0.23%)
Day range$12.83 – $14.51
Volume676,061
Market cap$1.89B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.89B
Price / earnings
—
Price / book
6.26×
Price / sales
—
EV / sales
—
EV / EBITDA
-26.67×
Profitability
Earnings per share
-$0.43
Return on assets
-19.55%
Return on equity
-20.07%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
38.86×
Quick ratio
38.86×
Cash ratio
3.54×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$61.69M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TRVI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$5.42M
$5.36M
$4.97M
$4.03M
$3.83M
$4.33M
$3.66M
$2.92M
Research and development
$19.06M
$15.15M
$9.94M
$6.19M
$10.09M
$9.39M
$7.81M
$9.33M
Total operating expenses
$24.49M
$20.51M
$14.91M
$10.22M
$13.92M
$13.72M
$11.47M
$12.24M
Operating income
-$24.49M
-$20.51M
-$14.91M
-$10.22M
-$13.92M
-$13.72M
-$11.47M
-$12.24M
Interest expense
$0
$0
$0
$0
$0
$0
$0
-$1K
Income before taxes
-$21.47M
-$17.82M
-$13.21M
-$8.33M
-$11.82M
-$12.32M
-$10.35M
-$11.4M
Income taxes
-$19K
-$19K
-$20K
-$16K
-$15K
-$21K
-$11K
$16K
Net income
-$21.45M
-$17.8M
-$13.19M
-$8.32M
-$11.8M
-$12.3M
-$10.34M
-$11.42M
Net income attributable to common shareholders
-$21.45M
-$17.8M
-$13.19M
-$8.32M
-$11.8M
-$12.3M
-$10.34M
-$11.42M
EBITDA
-$24.45M
-$20.48M
-$14.88M
-$10.19M
-$13.88M
-$13.68M
-$11.43M
-$12.21M
Basic earnings per share
-$0.13
-$0.11
-$0.09
-$0.06
-$0.08
-$0.09
-$0.09
-$0.11
Diluted earnings per share
-$0.13
-$0.11
-$0.09
-$0.06
-$0.08
-$0.09
-$0.09
-$0.11
Recent news
Company coverage with links to the original publishers.
Trevi Therapeutics announced that senior management will participate in two biotech conferences in August 2026, including Oppenheimer's Biotech in the Berkshires on August 4 and Stifel's 2026 Biotech Summer Summit on August 10-12. The company is developing Haduvio (oral nalbuphine ER) for treating chronic cough in patients with IPF, non-IPF ILD, and RCC, with clinical trials showing statistically significant reductions in cough frequency.
Trevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before underwriting costs. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis and other lung conditions. The offering is expected to close on April 20, 2026.
Trevi Therapeutics priced an underwritten public offering of 11.6 million shares at $13.00 per share, raising approximately $150 million before fees. The clinical-stage biopharmaceutical company is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF, non-IPF ILD, and refractory chronic cough patients. The offering is expected to close on April 20, 2026.
The chronic refractory cough market is projected to expand by 2034, driven by rising patient diagnoses, improved awareness, and emerging therapies targeting refractory cough conditions.
Law firm Kaskela Law LLC is investigating Trevi Therapeutics for potential securities law violations or breaches of fiduciary duties, encouraging long-term investors to contact them for more information.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.